Aptose Announces Deferral of Interest Payment

Core Insights - Aptose Biosciences Inc. has entered into an Interest Deferral Agreement with Hanmi Pharmaceutical Co., Ltd. to defer interest payments on a loan facility agreement [1] - The deferral period for the interest payments extends from December 21, 2024, to March 31, 2025, and from June 27, 2025, to December 31, 2025 [1] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [2] - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor showing efficacy as both a monotherapy and in combination therapy for relapsed or refractory acute myeloid leukemia (AML) [2] - Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed AML patients [2]